Loss of Nogo-A-expressing neurons in a rat model of Parkinson's disease

Neuroscience

Volumn 288, Issue , 2015, Pages 59-72

  Schawkat, K ^a   Di Santo, S ^a   Seiler, S ^a   Ducray, A D ^a   Widmer, H R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

6 OHDA lesion; Midbrain; Nogo A; Parkinson's disease

Indexed keywords

OXIDOPAMINE; PROTEIN NOGO A; 2-HYDROXY-4,4'-DIAMIDINOSTILBENE, METHANESULFONATE SALT; CELL NUCLEUS ANTIGEN; CHOLINE ACETYLTRANSFERASE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MYELIN PROTEIN; NERVE PROTEIN; NEUN PROTEIN, RAT; PROTEIN NOGO; STILBAMIDINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NERVE CELL PLASTICITY; NERVE FIBER REGENERATION; NONHUMAN; PARKINSON DISEASE; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL MESENCEPHALON; ANIMAL; CELL COUNT; METABOLISM; MICROPHOTOGRAPHY; NERVE CELL; NEUROANATOMICAL TRACT TRACING; PARKINSONISM; PATHOLOGY; SPINAL CORD; WISTAR RAT;

ANIMALS; ANTIGENS, NUCLEAR; CELL COUNT; CHOLINE O-ACETYLTRANSFERASE; DOPAMINE; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MYELIN PROTEINS; NERVE TISSUE PROTEINS; NEUROANATOMICAL TRACT-TRACING TECHNIQUES; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOTOMICROGRAPHY; RATS, WISTAR; SPINAL CORD; STILBAMIDINES; TYROSINE 3-MONOOXYGENASE;

EID: 84921038681     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.12.035     Document Type: Article

References (50)

1. Baimbridge K.G., Celio M.R., Rogers J.H. Calcium-binding proteins in the nervous system. Trends Neurosci 1992, 15:303-308.
2. Bossers K., Meerhoff G., Balesar R., van Dongen J.W., Kruse C.G., Swaab D.F., Verhaagen J. Analysis of gene expression in Parkinson's disease: possible involvement of neurotrophic support and axon guidance in dopaminergic cell death. Brain Pathol 2009, 19:91-107.
3. Cannon C.J., Greenamyre J.T. NeuN is not a reliable marker of dopamine nuerons in rat substantia nigra. Neurosci Lett 2009, 464:14-17.
4. Craveiro L.M., Hakkoum D., Weinmann O., Montani L., Stoppini L., Schwab M.E. Neutralization of the membrane protein Nogo-A enhances growth and reactive sprouting in established organotypic hippocampal slice cultures. Eur J Neurosci 2008, 28:1808-1824.
5. Dodd D.A., Niederoest B., Bloechlinger S., Dupuis L., Loeffler J.P., Schwab M.E. Nogo-A, -B, and -C are found on the cell surface and interact together in many different cell types. J Biol Chem 2005, 280:12494-12502.
6. Funahashi S., Hasegawa T., Nagano A., Sato K. Differential expression patterns of messenger RNAs encoding Nogo receptors and their ligands in the rat central nervous system. J Comp Neurol 2008, 506:141-160.
7. Gao Y., Xiao Z., Chen B., Wang B., Han J., Zhao Y., Zhang J., Dai J. Effect of different regions of Nogo-A on the differentiation of neural progenitors. Neurosci Lett 2009, 458:132-135.
8. German D.C., Manaye K.F., Sonsalla P.K., Brooks B.A. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 1992, 648:42-62.
9. Gil V., Nicolas O., Mingorance A., Urena J.M., Tang B.L., Hirata T., Saez-Valero J., Ferrer I., Soriano E., del Rio J.A. Nogo-A expression in the human hippocampus in normal aging and in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:433-444.
10. Gombash S.E., Lipton J.W., Collier T.J., Madhavan L., Steece-Collier K., Cole-Strauss A., Terpstra B.T., Spieles-Engemann A.L., Daley B.F., Wohlgenant S.L., Thompson V.B., Manfredsson F.P., Mandel R.J., Sortwell C.E. Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Mol Ther 2012, 20:544-554.
11. Gonzalez-Hernandez T., Barroso-Chinea P., De La Cruz Muros I., Del Mar Perez-Delgado M., Rodriguez M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J Comp Neurol 2004, 479:198-215.
12. Hasegawa T., Ohno K., Sano M., Omura T., Omura K., Nagano A., Sato K. The differential expression patterns of messenger RNAs encoding Nogo-A and Nogo-receptor in the rat central nervous system. Brain Res Mol Brain Res 2005, 133:119-130.
13. Heizmann C.W. Calcium-binding proteins: basic concepts and clinical implications. Gen Physiol Biophys 1992, 11:411-425.
14. Huber A.B., Weinmann O., Brosamle C., Oertle T., Schwab M.E. Patterns of Nogo mRNA and protein expression in the developing and adult rat and after CNS lesions. J Neurosci 2002, 22:3553-3567.
15. Hunt D., Coffin R.S., Prinjha R.K., Campbell G., Anderson P.N. Nogo-A expression in the intact and injured nervous system. Mol Cell Neurosci 2003, 24:1083-1102.
16. Inoue H., Lin L., Lee X., Shao Z., Mendes S., Snodgrass-Belt P., Sweigard H., Engber T., Pepinsky B., Yang L., Beal M.F., Mi S., Isacson O. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc Natl Acad Sci U S A 2007, 104:14430-14435.
17. Jiang W., Xia F., Han J., Wang J. Patterns of Nogo-A, NgR, and RhoA expression in the brain tissues of rats with focal cerebral infarction. Transl Res 2009, 154:40-48.
18. Jokic N., Gonzalez de Aguilar J.L., Pradat P.F., Dupuis L., Echaniz-Laguna A., Muller A., Dubourg O., Seilhean D., Hauw J.J., Loeffler J.P., Meininger V. Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 2005, 57:553-556.
19. Josephson A., Trifunovski A., Widmer H.R., Widenfalk J., Olson L., Spenger C. Nogo-receptor gene activity: cellular localization and developmental regulation of mRNA in mice and humans. J Comp Neurol 2002, 453:292-304.
20. Kristofikova Z., Vrajova M., Sirova J., Vales K., Petrasek T., Schonig K., Tews B., Schwab M., Bartsch D., Stuchlik A., Ripova D. N-methyl-d-aspartate receptor - nitric oxide synthase pathway in the cortex of Nogo-A-deficient rats in relation to brain laterality and schizophrenia. Front Behav Neurosci 2013, 7:90.
21. Kurowska Z., Brundin P., Schwab M.E., Li J.Y. Intracellular Nogo-A facilitates initiation of neurite formation in mouse midbrain neurons in vitro. Neuroscience 2014, 256:456-466.
22. Lesnick T.G., Papapetropoulos S., Mash D.C., Ffrench-Mullen J., Shehadeh L., de Andrade M., Henley J.R., Rocca W.A., Ahlskog J.E., Maraganore D.M. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet 2007, 3:e98.
23. Meyer M., Widmer H.R., Wagner B., Guzman R., Evtouchenko L., Seiler R.W., Spenger C. Comparison of mesencephalic free-floating tissue culture grafts and cell suspension grafts in the 6-hydroxydopamine-lesioned rat. Exp Brain Res 1998, 119:345-355.
24. Montani L., Gerrits B., Gehrig P., Kempf A., Dimou L., Wollscheid B., Schwab M.E. Neuronal Nogo-A modulates growth cone motility via Rho-GTP/LIMK1/cofilin in the unlesioned adult nervous system. J Biol Chem 2009, 284:10793-10807.
25. Mouatt-Prigent A., Agid Y., Hirsch E.C. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?. Brain Res 1994, 668:62-70.
26. Nagamoto-Combs K., Morecraft R.J., Darling W.G., Combs C.K. Long-term gliosis and molecular changes in the cervical spinal cord of the rhesus monkey after traumatic brain injury. J Neurotrauma 2010, 27:565-585.
27. Nyatia E., Lang D.M. Localisation and expression of a myelin associated neurite inhibitor, Nogo-A and its receptor Nogo-receptor by mammalian CNS cells. Res Vet Sci 2007, 83:287-301.
28. Pisani A., Bonsi P., Picconi B., Tolu M., Giacomini P., Scarnati E. Role of tonically-active neurons in the control of striatal function: cellular mechanisms and behavioral correlates. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:211-230.
29. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
30. Rodriguez M., Barroso-Chinea P., Abdala P., Obeso J., Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp Neurol 2001, 169:163-181.
31. Rogers J.H. Immunohistochemical markers in rat cortex: co-localization of calretinin and calbindin-D28k with neuropeptides and GABA. Brain Res 1992, 587:147-157.
32. Rosenblad C., Kirik D., Devaux B., Moffat B., Phillips H.S., Bjorklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999, 11:1554-1566.
33. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
34. Schmued L.C., Fallon J.H. Fluoro-Gold: a new fluorescent retrograde axonal tracer with numerous unique properties. Brain Res 1986, 377:147-154.
35. Schwab J.M., Tuli S.K., Failli V. The Nogo receptor complex: confining molecules to molecular mechanisms. Trends Mol Med 2006, 12:293-297.
36. Schwab M.E. Nogo and axon regeneration. Curr Opin Neurobiol 2004, 14:118-124.
37. Schwab M.E., Strittmatter S.M. Nogo limits neural plasticity and recovery from injury. Curr Opin Neurobiol 2014, 27C:53-60.
38. Seiler S., Pollini D., Di Santo S., Widmer H.R. Antagonizing Nogo-receptor 1 promotes the number of cultured dopaminergic neurons and elongates their neurites. NeuroReport 2013, 24:1047-1052.
39. Shin J.W., Shim E.S., Hwang G.H., Jung H.S., Park J.H., Sohn N.W. Cell size-dependent Nogo-A expression in layer V pyramidal neurons of the rat primary somatosensory cortex. Neurosci Lett 2006, 394:117-120.
40. Simonen M., Pedersen V., Weinmann O., Schnell L., Buss A., Ledermann B., Christ F., Sansig G., van der Putten H., Schwab M.E. Systemic deletion of the myelin-associated outgrowth inhibitor Nogo-A improves regenerative and plastic responses after spinal cord injury. Neuron 2003, 38:201-211.
41. Theotokis P., Lourbopoulos A., Touloumi O., Lagoudaki R., Kofidou E., Nousiopoulou E., Poulatsidou K.N., Kesidou E., Tascos N., Spandou E., Grigoriadis N. Time course and spatial profile of Nogo-A expression in experimental autoimmune encephalomyelitis in C57BL/6 mice. J Neuropathol Exp Neurol 2012, 71:907-920.
42. Wang F., Liang Z., Hou Q., Xing S., Ling L., He M., Pei Z., Zeng J. Nogo-A is involved in secondary axonal degeneration of thalamus in hypertensive rats with focal cortical infarction. Neurosci Lett 2007, 417:255-260.
43. Wang F., Xing S., He M., Hou Q., Chen S., Zou X., Pei Z., Zeng J. Nogo-A is associated with secondary degeneration of substantia nigra in hypertensive rats with focal cortical infarction. Brain Res 2012, 1469:153-163.
44. Wang H., Yao Y., Jiang X., Chen D., Xiong Y., Mu D. Expression of Nogo-A and NgR in the developing rat brain after hypoxia-ischemia. Brain Res 2006, 1114:212-220.
45. Wang X., Chun S.J., Treloar H., Vartanian T., Greer C.A., Strittmatter S.M. Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 2002, 22:5505-5515.
46. Williams P.T., Kim S., Martin J.H. Postnatal maturation of the red nucleus motor map depends on rubrospinal connections with forelimb motor pools. J. Neurosci 2014, 34:4432-4441.
47. Willi R., Aloy E.M., Yee B.K., Feldon J., Schwab M.E. Behavioral characterization of mice lacking the neurite outgrowth inhibitor Nogo-A. Genes Brain Behav 2009, 8:181-192.
48. Yamada T., McGeer P.L., Baimbridge K.G., McGeer E.G. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990, 526:303-307.
49. Yang Y., Liu Y., Wei P., Peng H., Winger R., Hussain R.Z., Ben L.H., Cravens P.D., Gocke A.R., Puttaparthi K., Racke M.K., McTigue D.M., Lovett-Racke A.E. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol 2010, 67:498-507.
50. Zörner B., Schwab M.E. Anti Nogo on the go: from animal models to clinical trials. Ann N Y Acad Sci 2010, 1198(Suppl. 1):E22-E34.